<DOC>
	<DOCNO>NCT02556931</DOCNO>
	<brief_summary>To see possible use short-duration tacrolimus peripheral blood stem cell transplant certain malignancy consider difficult engraft .</brief_summary>
	<brief_title>Shorter Course Tacro After NMA , Related Donor PBSCT With High-dose Posttransplant Cy Hard-to-Engraft Malignancies</brief_title>
	<detailed_description>The main goal learn whether drug call tacrolimus , immune-lowering drug ( immunosuppressant ) give transplant help prevent certain complication , give safely short period time past . The experience immunosuppression duration allogeneic HSCT platform directly extrapolate high-dose posttransplantation cyclophosphamide platform ( another type immunosuppressant give transplant help prevent GVHD ) . There presently publish data minimum require duration tacrolimus nonmyeloablative HSCT include high-dose Cy part postgrafting immunosuppression . The effectiveness high-dose posttransplantation Cy GVHD prevention , however , permit investigation question . At present time cure disease study trial outside bone marrow peripheral blood transplant . The peripheral blood transplant come relative half-match `` haplo '' match participant . Possible donor include parent , sibling , child . In order help bone marrow grow , `` take '' , inside body , participant receive chemotherapy radiation transplant . After transplant participant receive high dos cyclophosphamide ( CytoxanÂ® ) along medication low immune system , tacrolimus . These medication may lower risk graft versus host disease ( GVHD ) rejection peripheral blood graft .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Plasma Cell</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Presence suitable related HLAhaploidentical match stem cell donor , 10/10 match unrelated donor Eligible diagnosis : myelodysplastic syndrome ( MDS ) least 1 poorrisk feature ; small lymphocytic lymphoma ( SLL ) chronic lymphocytic leukemia ( CLL ) 17p deletion progression &lt; 6 month second great treatment regimen ; Tcell prolymphocytic leukemia ( PLL ) partial response well ; interferon tyrosinekinaserefractory chronic myeloid leukemia ( CML ) , CML second subsequent chronic phase ; Philadelphia chromosome negative ( Ph ) myeloproliferative disease , include myelofibrosis ; Multiple myeloma plasma cell leukemia partial response well Any previous autologous transplant must occur &gt; 3 month ago Left ventricular ejection fraction ( LVEF ) &gt; = 35 % , shorten fraction &gt; 25 % Bilirubin &lt; = 3.0 mg/dL ( unless due Gilbert 's syndrome hemolysis ) AST ALT &lt; = 5 x institutional upper limit normal FEV1 FVC &gt; = 40 % predict ; unable perform pulmonary function testing , oxygen saturation &gt; 92 % room air ECOG performance status &lt; = 2 , Karnofsky/Lansky status &gt; = 60 Pregnancy active breastfeeding Uncontrolled active infection Previous allogeneic transplant Active extramedullary leukemia active central nervous system ( CNS ) malignant disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>immunosuppression</keyword>
	<keyword>nonmyeloablative</keyword>
	<keyword>non-myeloablative</keyword>
	<keyword>allogeneic</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>peripheral blood</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>mycophenolate mofetil</keyword>
</DOC>